0000000000701239

AUTHOR

Morten Karsdal

0000-0001-5026-8740

showing 9 related works from this author

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis

2021

[Background and Aims] Vibration-controlled transient elastography (VCTE), point shear wave elastography (pSWE), 2-dimensional shear wave elastography (2DSWE), magnetic resonance elastography (MRE), and magnetic resonance imaging (MRI) have been proposed as non-invasive tests for patients with non-alcoholic fatty liver disease (NAFLD). This study evaluated their diagnostic accuracy for liver fibrosis and non-alcoholic steatohepatitis (NASH).

0301 basic medicineFIBROSIS NONINVASIVE ASSESSMENTCirrhosisTransient elastographydeMILI0302 clinical medicineMedicineBARIATRIC SURGERY CANDIDATESNon-alcoholic steatohepatitismedicine.diagnostic_testNONALCOHOLIC STEATOHEPATITISFatty liverMagnetic Resonance Imaging3. Good healthArea Under CurveLiver biopsyElasticity Imaging TechniquesNASH-MRI030211 gastroenterology & hepatologyBio-markersRadiologyElastographyDiffusion-weighted imagingLife Sciences & BiomedicineAdultPREDICTS ADVANCED FIBROSISmedicine.medical_specialtyBiomarkers deMILI Diffusion-weighted imaging Magnetic resonance elastography NASH-MRI Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis Shear wave elastography Transient elastography AdultArea Under Curve Elasticity Imaging Techniques Humans Magnetic Resonance Imaging Non-alcoholic Fatty Liver Disease ROC Curve fibro-MRI Iron-corrected T1 Liver fibrosisLiver fibrosisCONTROLLED ATTENUATION PARAMETERSTIFFNESS MEASUREMENT03 medical and health sciencesIron-corrected T1HumansFATTY LIVER-DISEASEScience & TechnologyHepatologyGastroenterology & Hepatologybusiness.industryRADIATION FORCE IMPULSEMagnetic resonance imagingmedicine.diseaseCONTROLLED TRANSIENT ELASTOGRAPHYMagnetic resonance elastography030104 developmental biologyROC CurveMagnetic resonance elastographyShear wave elastographyXL PROBEHuman medicinefibro-MRISteatohepatitisbusinessTransient elastographyBiomarkersNon-alcoholic fatty liver diseaseJournal of Hepatology
researchProduct

Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C.

2014

BACKGROUND & AIMS: Fibrogenesis results in release of certain extracellular matrix protein fragments into the circulation. We evaluated the diagnostic and prognostic performance of two novel serological markers, the precisely cleaved N-terminal propeptide of type III collagen (Pro-C3) and a peptide of helical collagen type III degradation (C3M), in chronic hepatitis C (CHC) patients. METHOD: Pro-C3 and C3M were measured by ELISA in plasma from CHC patients (n = 194) from a prior phase II antifibrotic trial (NCT00244751). Plasma samples and paired liver biopsies were obtained at baseline and after 1-year. Patients were stratified according to Ishak stages 2-4. Internal cross-validation w…

Liver CirrhosisCollagen Type III/bloodPathologymedicine.medical_specialtyLiver fibrosisEnzyme-Linked Immunosorbent AssayGastroenterologySerologyExtracellular matrixCohort StudiesCollagen Type IIIFibrosisPredictive Value of TestsInternal medicinemedicineHumansStage (cooking)Hepatologybusiness.industryFibroTestBiomarkerHepatitis C ChronicPrognosismedicine.diseaseCollagen Type IIIPredictive value of testsMultivariate AnalysisExtracellular matrix remodellingDisease ProgressionBiomarker (medicine)Hepatitis C Chronic/bloodbusinessLiver Cirrhosis/diagnosisBiomarkers/bloodBiomarkersLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Inducible knockdown of procollagen I protects mice from liver fibrosis and leads to dysregulated matrix genes and attenuated inflammation.

2017

Organ fibrosis is characterized by a chronic wound-healing response, with excess deposition of extracellular matrix components. Here, collagen type I represents the most abundant scar component and a primary target for antifibrotic therapies. Liver fibrosis can progress to cirrhosis and primary liver cancer, which are the major causes of liver related morbidity and mortality. However, a (pro-)collagen type I specific therapy remains difficult and its therapeutic abrogation may incur unwanted side effects. We therefore designed tetracycline-regulated procollagen alpha1(I) short hairpin (sh)RNA expressing mice that permit a highly efficient inducible knockdown of the procollagen alpha1(I) gen…

0301 basic medicineGenetically modified mouseLiver CirrhosisPathologymedicine.medical_specialtyCirrhosisInflammationMice TransgenicCollagen Type ISmall hairpin RNAExtracellular matrix03 medical and health sciencesMiceFibrosismedicineAnimalsRNA Small InterferingMolecular BiologyCells CulturedGene knockdownExtracellular Matrix ProteinsChemistryMouse Embryonic Stem CellsFibroblastsmedicine.diseaseProcollagen peptidaseDisease Models Animal030104 developmental biologyGene Expression RegulationGene Knockdown TechniquesCancer researchmedicine.symptomProcollagenMatrix biology : journal of the International Society for Matrix Biology
researchProduct

Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.

2019

Background & Aim There is an unmet need for non-invasive biomarkers in non-alcoholic fatty liver disease (NAFLD) that can diagnose advanced disease and identify patients suitable for clinical trials. The PRO-C3 collagen neo-epitope is a putative direct marker of fibrogenesis. We assessed the performance of PRO-C3 in a large, well-characterised international NAFLD cohort and report the development and validation of 2 novel panels for the diagnosis of advanced fibrosis (F≥3) in NAFLD, including a simplified clinical score which eliminates the need for online calculators. Methods Plasma PRO-C3 levels were determined in a prospectively recruited international cohort of 449 patients with biopsy …

medicine.medical_specialtyADVANCED FIBROSISSCORING SYSTEMPROGRESSIONGastroenterologySTEATOHEPATITIS03 medical and health sciences0302 clinical medicineFibrosisInternal medicineNAFLDBiopsyInternal MedicineImmunology and AllergyMedicineSTEATOSISPRO-C3Stage (cooking)lcsh:RC799-869030304 developmental biologySteatohepatitisRISK0303 health sciencesScience & TechnologyHepatologymedicine.diagnostic_testGastroenterology & Hepatologybusiness.industryFatty liverfibrosisGastroenterologyNASHDIABETES-MELLITUSCHRONIC HEPATITISBiomarkermedicine.disease3. Good healthClinical trialCohortBIOPSYBiomarker (medicine)030211 gastroenterology & hepatologylcsh:Diseases of the digestive system. GastroenterologySteatohepatitisbusinessLife Sciences & BiomedicineResearch ArticleJHEP reports : innovation in hepatology
researchProduct

A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Pati…

2020

INTRODUCTION Metabolic-associated fatty liver disease is common, with fibrosis the major determinant of adverse outcomes. Population-based screening tools with high diagnostic accuracy for the staging of fibrosis are lacking. METHODS Three independent cohorts, 2 with both liver biopsy and liver stiffness measurements (LSMs, n = 254 and 65) and a population sample (n = 713), were studied. The performance of a recently developed noninvasive algorithm (ADAPT [age, diabetes, PRO-C3 and platelets panel]) as well as aspartate aminotransferase-to-platelet ratio index, fibrosis-4, nonalcoholic fatty liver disease fibrosis score, and LSM was used to stage patients for significant (≥F2) and advanced …

Malemedicine.medical_specialtyBiopsyPopulationGastroenterology03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseasePredictive Value of TestsDiabetes mellitusInternal medicineNonalcoholic fatty liver diseasemedicineDiabetes MellitusHumansAspartate Aminotransferaseseducationeducation.field_of_studyHepatologymedicine.diagnostic_testReceiver operating characteristicbusiness.industryPlatelet CountFatty liverGastroenterologyAge FactorsOdds ratioMiddle Agedmedicine.diseaseCollagen Type III030220 oncology & carcinogenesisLiver biopsyElasticity Imaging Techniques030211 gastroenterology & hepatologyFemalebusinessAlgorithmsBiomarkersThe American journal of gastroenterology
researchProduct

Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program

2019

BACKGROUND Lifestyle modifications remain the cornerstone of treatment in non-alcoholic fatty liver disease (NAFLD). However, they requently fail related to the inability of patients to implement lasting changes. AIMS To evaluate the effects of a short, web-based, individualised exercise program on non-invasive markers of hepatic steatosis, inflammation and fibrosis. METHODS Patients with histologically confirmed NAFLD underwent an 8-week, web-based, individualised exercise program that contained bidirectional feedback. RESULTS Forty-four patients entered the study and 41 completed the assigned training goal (93.2%). In the completer population, 8 weeks of individualised exercise increased …

AdultMalemedicine.medical_specialtyPopulationGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineMedicineHumansPharmacology (medical)030212 general & internal medicineYoung adultExercise physiologyPrecision MedicineeducationExerciseLife Styleeducation.field_of_studyInternetHepatologybusiness.industryFatty liverGastroenterologyMiddle Agedmedicine.disease3. Good healthExercise TherapyQuality of LifeElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleSteatosisbusinessHepatic fibrosisTransient elastographyBiomarkersAlimentary Pharmacology & Therapeutics
researchProduct

Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential an…

2016

There are no approved treatments for liver fibrosis. To aid development of antifibrotic therapies, noninvasive biomarkers that can identify patients with progressive fibrosis and that permit monitoring of the response to antifibrotic therapy are much needed. Samples from a phase II antifibrotic trial of the glitazone farglitazar in patients with advanced hepatitis C, with matched follow-up liver biopsies, and from a phase III study of balaglitazone in patients with late-stage Type 2 diabetes (BALLET study) were analyzed for serological Pro-C3 levels in conjunction with other disease parameters. In the farglitazar study, a predefined cutoff value for Pro-C3 as a selection criterion led to t…

Liver CirrhosisMale0301 basic medicineNonalcoholic steatohepatitisPathologymedicine.medical_specialtyPhysiologyLiver fibrosisType 2 diabetesSerology03 medical and health sciencesCollagen formation0302 clinical medicineFibrosisSerum biomarkersPhysiology (medical)Journal ArticlemedicineHumansOxazolesType III collagenHepatologybusiness.industryPatient SelectionGastroenterologyMiddle Agedmedicine.disease3. Good healthCollagen Type III030104 developmental biologyQuinazolinesTyrosineFemaleThiazolidinediones030211 gastroenterology & hepatologybusinessBiomarkersAmerican Journal of Physiology-Gastrointestinal and Liver Physiology
researchProduct

Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance

2022

Background & Aims Serum microRNA (miRNA) levels are known to change in non-alcoholic fatty liver disease (NAFLD) and may serve as useful biomarkers. This study aimed to profile miRNAs comprehensively at all NAFLD stages. Methods We profiled 2,083 serum miRNAs in a discovery cohort (183 cases with NAFLD representing the complete NAFLD spectrum and 10 population controls). miRNA libraries generated by HTG EdgeSeq were sequenced by Illumina NextSeq. Selected serum miRNAs were profiled in 372 additional cases with NAFLD and 15 population controls by quantitative reverse transcriptase PCR. Results Levels of 275 miRNAs differed between cases and population controls. Fewer differences were seen wi…

SCORING SYSTEMCPM counts per millionAUROC area under the receiver operating characteristicRC799-869AST aspartate aminotransferaseMicroRNA; Non-alcoholic fatty liver disease; Biomarker; SequencingTGF-β transforming growth factor-betaGastroenterologySTEATOHEPATITISLiver disease0302 clinical medicineFibrosismiRNA microRNAlogFC log2 fold changeFIBROSISImmunology and AllergySequencing0303 health scienceseducation.field_of_studyNAS NAFLD activity scoremedicine.diagnostic_testFatty liverGastroenterologyGTEx Genotype-Tissue ExpressionMicroRNADiseases of the digestive system. Gastroenterology3. Good healthReal-time polymerase chain reactionBiomarker MicroRNA Non-alcoholic fatty liver disease SequencingLiver biopsyACIDBiomarker (medicine)030211 gastroenterology & hepatologyLife Sciences & BiomedicineResearch ArticleEXPRESSIONmedicine.medical_specialtyNAFLD non-alcoholic fatty liver diseaseNASH non-alcoholic steatohepatitisPopulationGastroenterology and HepatologySAF steatosis–activity–fibrosisVALIDATIONER endoplasmic reticulum03 medical and health sciencescDNA complementary DNAInternal medicineALT alanine aminotransferaseGastroenterologiInternal MedicinemedicineNAFL non-alcoholic fatty liverALGORITHMFIB-4 fibrosis-4education030304 developmental biologyPCA principal component analysisScience & TechnologyGastroenterology & HepatologyHepatologybusiness.industryBiomarkerFC fold changemedicine.diseaseBiomarker; MicroRNA; Non-alcoholic fatty liver disease; Sequencingdigestive system diseasesFLIP fatty liver inhibition of progressionCt cycle thresholdSteatosisqPCR quantitative PCRbusinessNon-alcoholic fatty liver disease
researchProduct

Is the Total Amount as Important as Localization and Type of Collagen in Liver Fibrosis Attributable to Steatohepatitis?

2020

Is liver fibrosis just liver fibrosis? Or do the subtype of collagen, its spatial localization in the liver, its cell of origin, and the time point at which it is synthesized also matter? It is important, since the various collagen subtypes hold different informative values regarding reparative processes in the liver, and as collagens have also emerged as important signaling molecules (1). Novel data have challenged our perception of liver fibrosis and collagens, which may have important implications regarding the development of new biomarkers and anti-fibrotic interventions. The traditional histological analysis of liver biopsies using histochemical collagen stains, such as the Masson's Tr…

Liver Cirrhosis0303 health sciencesPathologymedicine.medical_specialtyHepatologybusiness.industryLiver fibrosismedicine.diseaseFatty Liver03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesismedicineAnimalsHumansCollagenSteatohepatitisbusiness030304 developmental biology
researchProduct